Ofev and Yellow skin - a phase IV clinical study of FDA data

Summary:

Yellow skin is found among people who take Ofev, especially for people who are male, 60+ old, have been taking the drug for 1 - 6 months.

The phase IV clinical study analyzes which people take Ofev and have Yellow skin. It is created by eHealthMe based on reports of 21,313 people who have side effects when taking Ofev from the FDA, and is updated regularly. You can use the study as a second opinion to make health care decisions.

Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.

On Sep, 18, 2023

21,313 people reported to have side effects when taking Ofev.
Among them, 17 people (0.08%) have Yellow skin.

What is Ofev?

Ofev has active ingredients of nintedanib esylate. eHealthMe is studying from 21,341 Ofev users for its effectiveness, alternative drugs and more.

What is Yellow skin?

Yellow skin is found to be associated with 1,464 drugs and 1,060 conditions by eHealthMe.

Number of Ofev and Yellow skin reports submitted per year:

Time on Ofev when people have Yellow skin *:

Gender of people who have Yellow skin when taking Ofev *:

female: 41.18 %
male: 58.82 %

Age of people who have Yellow skin when taking Ofev *:

Common drugs people take besides Ofev *:

Common side effects people have besides Yellow skin *:

Diarrhea: 9 people, 52.94%
Weight Decreased: 7 people, 41.18%
Fatigue (feeling of tiredness): 7 people, 41.18%
Nausea (feeling of having an urge to vomit): 7 people, 41.18%
Appetite - Decreased (decreased appetite occurs when you have a reduced desire to eat): 6 people, 35.29%
Abdominal Pain Upper: 6 people, 35.29%
Abdominal Pain: 6 people, 35.29%
Headache (pain in head): 5 people, 29.41%
Weakness: 5 people, 29.41%
Pain: 5 people, 29.41%

Common conditions people have *:

Idiopathic Pulmonary Fibrosis (chronic lung disease): 17 people, 100.00%
Pain: 2 people, 11.76%
Quit Smoking: 1 person, 5.88%
Interstitial Lung Disease: 1 person, 5.88%
Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 1 person, 5.88%
Depression: 1 person, 5.88%

* Approximation only. Some reports may have incomplete information.

Do you take Ofev and have Yellow skin?

Check whether Yellow skin is associated with a drug or a condition

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.

Related studies

How severe was Yellow skin and when was it recovered:

Yellow skin in Ofev

Expand to all the drugs that have ingredients of nintedanib esylate:

Yellow skin and drugs with ingredients of nintedanib esylate

Alternative drugs to, pros and cons of Ofev:

Ofev (21,341 reports)

Common Ofev side effects:

Browse all side effects of Ofev:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Yellow skin treatments and more:

Yellow skin (5,629 reports)

COVID vaccines that are related to Yellow skin:

Common drugs associated with Yellow skin:

All the drugs that are associated with Yellow skin:

Yellow skin (1,464 drugs)

Common conditions associated with Yellow skin:

High blood pressure: 326 reports
Renal cell carcinoma: 291 reports
Multiple sclerosis: 236 reports
High blood cholesterol: 156 reports
Pain: 154 reports

All the conditions that are associated with Yellow skin:

Yellow skin (1,060 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on nintedanib esylate (the active ingredients of Ofev) and Ofev (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.